Blood disorders typically associated with renal transplantation
- PMID: 25853131
- PMCID: PMC4365751
- DOI: 10.3389/fcell.2015.00018
Blood disorders typically associated with renal transplantation
Abstract
Renal transplantation has become one of the most common surgical procedures performed to replace a diseased kidney with a healthy kidney from a donor. It can help patients with kidney failure live decades longer. However, renal transplantation also faces a risk of developing various blood disorders. The blood disorders typically associated with renal transplantation can be divided into two main categories: (1) Common disorders including post-transplant anemia (PTA), post-transplant lymphoproliferative disorder (PTLD), post-transplant erythrocytosis (PTE), and post-transplant cytopenias (PTC, leukopenia/neutropenia, thrombocytopenia, and pancytopenia); and (2) Uncommon but serious disorders including hemophagocytic syndrome (HPS), thrombotic microangiopathy (TMA), therapy-related myelodysplasia (t-MDS), and therapy-related acute myeloid leukemia (t-AML). Although many etiological factors involve the development of post-transplant blood disorders, immunosuppressive agents, and viral infections could be the two major contributors to most blood disorders and cause hematological abnormalities and immunodeficiency by suppressing hematopoietic function of bone marrow. Hematological abnormalities and immunodeficiency will result in severe clinical outcomes in renal transplant recipients. Understanding how blood disorders develop will help cure these life-threatening complications. A potential therapeutic strategy against post-transplant blood disorders should focus on tapering immunosuppression or replacing myelotoxic immunosuppressive drugs with lower toxic alternatives, recognizing and treating promptly the etiological virus, bacteria, or protozoan, restoring both hematopoietic function of bone marrow and normal blood counts, and improving kidney graft survival.
Keywords: bone marrow suppression; clinical features; immunosuppressive agents; impaired hematopoiesis; post-transplant blood disorders; renal transplantation; therapeutic strategy; viral infections.
Similar articles
-
Haematological disorders following kidney transplantation.Nephrol Dial Transplant. 2022 Feb 25;37(3):409-420. doi: 10.1093/ndt/gfaa219. Nephrol Dial Transplant. 2022. PMID: 33150431 Review.
-
Hematologic disorders after solid organ transplantation.Hematology Am Soc Hematol Educ Program. 2010;2010:281-6. doi: 10.1182/asheducation-2010.1.281. Hematology Am Soc Hematol Educ Program. 2010. PMID: 21239807 Review.
-
Hematologic abnormalities following renal transplantation.Int Urol Nephrol. 2010 Mar;42(1):151-64. doi: 10.1007/s11255-009-9558-5. Epub 2009 Mar 20. Int Urol Nephrol. 2010. PMID: 19301140 Review.
-
Post-transplant lymphoproliferative disorders after live donor renal transplantation.Clin Transplant. 2005 Oct;19(5):668-73. doi: 10.1111/j.1399-0012.2005.00406.x. Clin Transplant. 2005. PMID: 16146560
-
Physician Education: Myelodysplastic Syndrome.Oncologist. 1996;1(4):284-287. Oncologist. 1996. PMID: 10388004
Cited by
-
Dialysis patients have comparable results to patients who have received kidney transplant after total joint arthroplasty: a systematic review and meta-analysis.EFORT Open Rev. 2021 Aug 10;6(8):618-628. doi: 10.1302/2058-5241.6.200116. eCollection 2021 Aug. EFORT Open Rev. 2021. PMID: 34532070 Free PMC article. Review.
-
Longitudinal Evaluation of Cytopenias in the Renal Transplant Population.Transplant Direct. 2022 May 26;8(6):e1339. doi: 10.1097/TXD.0000000000001339. eCollection 2022 Jun. Transplant Direct. 2022. PMID: 35651583 Free PMC article.
-
Post-transplant erythrocytosis after kidney transplantation: A review.World J Transplant. 2021 Jun 18;11(6):220-230. doi: 10.5500/wjt.v11.i6.220. World J Transplant. 2021. PMID: 34164297 Free PMC article. Review.
-
Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients.Front Pharmacol. 2018 Nov 14;9:1296. doi: 10.3389/fphar.2018.01296. eCollection 2018. Front Pharmacol. 2018. PMID: 30487748 Free PMC article.
-
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?Transpl Int. 2021 Dec;34(12):2442-2458. doi: 10.1111/tri.14115. Epub 2021 Oct 28. Transpl Int. 2021. PMID: 34555228 Free PMC article. Review.
References
-
- Abdelrahman M., Rafi A., Ghacha R., Qayyum T., Karkar A. (2004). Post-transplant erythrocytosis: a review of 47 renal transplant recipients. Saudi J. Kidney Dis. Transpl. 15, 433–439. - PubMed
-
- Ahmed S., Ahmed E., Naqvi R., Qureshi S. (2012). Evaluation of contributing factors of post transplant erythrocytosis in renal transplant patients. J. Pak. Med. Assoc. 62, 1326–1329. - PubMed
-
- Allen U., Hébert D., Moore D., Dror Y., Wasfy S. (2001). Canadian PTLD Survey Group–1998. Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Pediatr. Transplant. 5, 198–203. 10.1034/j.1399-3046.2001.00059.x - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous